Proprietary Products Division of Par Pharmaceutical with Initial Focus on
WOODCLIFF LAKE, N.J., Sept. 28 /PRNewswire-FirstCall/ - Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced its commitment to developing and marketing novel prescription drugs, through the establishment and introduction of Strativa Pharmaceuticals, its proprietary specialty pharmaceuticals division. Strativa Pharmaceuticals will provide the company's existing proprietary products division with a unique and recognizable identity in the marketplace -- to both healthcare providers and payers, as well as potential partners.
"Par has a long tradition of developing, manufacturing and marketing high-quality pharmaceuticals," said Patrick G. LePore, chairman, chief executive officer and president of Par. "Our Generics Division is a leader among U.S. generic drug companies, and we envision Strativa becoming a preeminent specialty pharmaceutical company. Strativa's unique focus will be to bring innovative proprietary pharmaceuticals to market. We consider this approach the best way to serve the needs of patients, while addressing unmet medical needs."
Strativa's current focus is on supportive care products for patients who are often critically ill. These therapeutics help patients manage complications from their illnesses or from the treatments they are receiving for those illnesses. Strativa's initial product offerings will be in HIV and oncology.
"Strativa is committed to providing treatment options to patients and
their healthcare providers," said John A. MacPhee, president of Strativa
Pharmaceuticals. "Our proprietary organization combines the energy and
innovation of a ne
|SOURCE Strativa Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved